Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Myelodysplastic Syndromes 92Leukemia, Myelogenous, Chronic, BCR-ABL Positive 82Leukemia, Myeloid, Acute 79Leukemia 41Myeloproliferative Disorders 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Multiple Myeloma 21Leukemia, Myeloid, Chronic-Phase 20Lymphoma, Non-Hodgkin 18Lymphoma 18Leukemia, Lymphocytic, Chronic, B-Cell 17Leukemia, Myelomonocytic, Chronic 16Polycythemia Vera 14Hodgkin Disease 14Primary Myelofibrosis 11Lymphoma, Large B-Cell, Diffuse 11Neoplasms, Plasma Cell 10Lymphoma, Follicular 10Hematologic Neoplasms 10Burkitt Lymphoma 10Recurrence 9Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 9Anemia, Refractory, with Excess of Blasts 9Myelodysplastic-Myeloproliferative Diseases 8Mastocytosis, Systemic 8Mastocytosis 8Lymphoma, Mantle-Cell 8Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, B-Cell, Marginal Zone 8Leukemia, Myeloid, Accelerated Phase 8

Interventions

masitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Piebaldism × Myeloid × Clear all
NCT04333108 2023-05-06

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

AB Science

Phase 3 Unknown
140 enrolled
Myeloid

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡